Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses the rationale of the phase 3 PROBE trial (NCT04510597) in advanced renal cell carcinoma (RCC).

The PROBE trial is an open-label study that will evaluate the efficacy of standard-of-care immunotherapy-based combinations with or without nephrectomy in patients with metastatic RCC. The PROBE trial is built on the phase 3 CARMENA trial (NCT00930033), which examined whether the addition of cytoreductive nephrectomy to standard treatment affects outcomes in patients with metastatic RCC, Vaishampayan explains. PROBE was designed because the treatment that was evaluated in CARMENA is no longer standard of care for metastatic kidney cancer, Vaishampayan adds.

The CARMENA trial examined treatment with sunitinib (Sutent) and showed that the addition of cytoreductive nephrectomy to sunitinib was noninferior to treatment with sunitinib alone, Vaishampayan continues. The PROBE trial is questioning whether cytoreductive nephrectomy will affect overall survival outcomes in a new treatment paradigm for metastatic kidney cancer, Vaishampayan concludes.